quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:51:00·41d
ANALYSTRating
Immutep Limited logo

Immutep downgraded by Maxim Group

IMMP· Immutep Limited
Health Care
Original source

Companies

  • IMMP
    Immutep Limited
    Health Care

Recent analyst ratings

  • Mar 13UpdateMaxim Group-
  • Mar 13UpdateRobert W. Baird$1.00
  • Mar 13UpdateCitizens-
  • Feb 17UpdateCitizens$6.00
  • May 17UpdateCapitalOne$10.00
  • Aug 3UpdateRobert W. Baird$7.00

Related

  • PR1d
    Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
  • INSIDER7d
    SEC Form 3 filed by new insider Boyce Elisabeth Amanda
  • SEC8d
    SEC Form 6-K filed by Immutep Limited
  • PR8d
    Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
  • INSIDER10d
    SEC Form 3 filed by new insider Voigt Marc
  • INSIDER10d
    SEC Form 3 filed by new insider Miller Deanne Diem
  • INSIDER16d
    SEC Form 3 filed by new insider Meyers Pete A.
  • INSIDER22d
    SEC Form 3 filed by new insider Winckels Stephan Karel Gerard
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022